Matheus Simonato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matheus Simonato has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Danny Dvir
Department of Cardiology, Shaare Zedek Medical Centre, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
5 shared publications - Philippe Pibarot
Université Laval
4 shared publications Alison Duncan
Department of Echocardiography, Royal Brompton Hospital, London, UK
3 shared publications- Jef Van Den Eynde
Department of Cardiovascular Diseases, UZ Leuven, Belgium (J.V.d.E., A.V.D.B., H.V.B., W.B.).
3 shared publications - Michel Pompeu Sá
Cleveland Clinic Florida
3 shared publications Alfredo Cerillo
Cardiochirurgia, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
2 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
Tricuspid inflow E-wave velocity for the assessment of severe or greater tricuspid regurgitation: derivation and external validation of threshold values
Aims: Current guidelines include tricuspid inflow E-wave (>100 cm/s by pulsed-wave Doppler) as a semiquantitative criterion for diagnosing severe tricuspid regurgitation (TR), despite limited supporting evidence. We assessed its diagnostic performance for identifying severe or greater TR, deriving and externally validating practical thresholds. Methods and results: Tricuspid inflow E-wave velocity was measured by pulsed-wave Doppler in consecutive patients with at least mild TR between December 2024 and February 2026. Among 178 patients (77 ± 13 years, 65% women), TR was mild in 44, moderate in 61, severe in 44, massive in 15, and torrential in 14. Mean tricuspid E-wave velocity was 56 ± 16 cm/s and increased with TR severity: 47 ± 8, 50 ± 10, 62 ± 16, 67 ± 13, and 77 ± 21 cm/s for mild, moderate, severe, massive, and torrential TR, respectively. Only three patients had E-wave velocity >100 cm/s (one with severe and two with torrential TR). Using multiparametric echocardiographic grading as the reference standard, the >100 cm/s threshold showed 5.5% sensitivity, 100% specificity, and kappa 0.25 for severe or greater TR. As a continuous variable, E-wave velocity discriminated severe or greater TR with an Area under the receiver operating characteristic curve of 0.81. A lower threshold of 52 cm/s yielded 81% sensitivity and 67% specificity, whereas 47 cm/s provided 90% sensitivity and 43% specificity. External validation resulted in 94% sensitivity and 47% specificity. Conclusion: The guideline-recommended threshold of >100 cm/s is highly insensitive for detecting severe or greater TR. Lower cut-offs, particularly 47 cm/s, may be useful for screening to trigger a comprehensive multiparametric assessment.
- 10 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
Open AccessTricuspid inflow E-wave velocity for the assessment of severe or greater tricuspid regurgitation: derivation and external validation of threshold values
Aims: Current guidelines include tricuspid inflow E-wave (>100 cm/s by pulsed-wave Doppler) as a semiquantitative criterion for diagnosing severe tricuspid regurgitation (TR), despite limited supporting evidence. We assessed its diagnostic performance for identifying severe or greater TR, deriving and externally validating practical thresholds. Methods and results: Tricuspid inflow E-wave velocity was measured by pulsed-wave Doppler in consecutive patients with at least mild TR between December 2024 and February 2026. Among 178 patients (77 ± 13 years, 65% women), TR was mild in 44, moderate in 61, severe in 44, massive in 15, and torrential in 14. Mean tricuspid E-wave velocity was 56 ± 16 cm/s and increased with TR severity: 47 ± 8, 50 ± 10, 62 ± 16, 67 ± 13, and 77 ± 21 cm/s for mild, moderate, severe, massive, and torrential TR, respectively. Only three patients had E-wave velocity >100 cm/s (one with severe and two with torrential TR). Using multiparametric echocardiographic grading as the reference standard, the >100 cm/s threshold showed 5.5% sensitivity, 100% specificity, and kappa 0.25 for severe or greater TR. As a continuous variable, E-wave velocity discriminated severe or greater TR with an Area under the receiver operating characteristic curve of 0.81. A lower threshold of 52 cm/s yielded 81% sensitivity and 67% specificity, whereas 47 cm/s provided 90% sensitivity and 43% specificity. External validation resulted in 94% sensitivity and 47% specificity. Conclusion: The guideline-recommended threshold of >100 cm/s is highly insensitive for detecting severe or greater TR. Lower cut-offs, particularly 47 cm/s, may be useful for screening to trigger a comprehensive multiparametric assessment.
- Open Access
- 21 March 2022
- Published by Elsevier in Structural Heart
- Vol. 5 (4) , 424-426
Severe Valvular Heart Disease and COVID-19: Results from the Multicenter International Valve Disease Registry
- 21 March 2022
- Published by Elsevier in Structural Heart
- Vol. 5 (4) , 424-426
Open AccessSevere Valvular Heart Disease and COVID-19: Results from the Multicenter International Valve Disease Registry
- 1 April 2021
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 14 (8) , 927-928
Reply
- 8 February 2021
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 98 (5) , E746-E757
Balloon versus self‐expandable transcatheter aortic valve implantation for bicuspid aortic valve stenosis: A meta‐analysis of observational studies
Background: There is a rising trend for transcatheter aortic valve implantation (TAVI) in bicuspid aortic stenosis patients. Data on the use of self‐expandable (SEV) vs. balloon‐expandable (BEV) valves in these patients are scarce. Therefore, we systematically compared clinical outcomes in bicuspid aortic stenosis patients treated with SEV and BEV.Methods: Data were extracted from PubMed/MEDLINE, EMBASE, CENTRAL/CCTR, ClinicalTrials.gov, SciELO, LILACS, Google Scholar and reference lists of relevant articles. Eight studies published from 2013 to 2020 including a total of 1,080 patients (BEV: n = 620; SEV: n = 460) were selected. Primary endpoints were procedural, 30‐day and 1‐year mortality. Secondary endpoints were new pacemaker implantation, annular rupture, coronary obstruction, moderate‐to‐severe paravalvular leak, need of second valve, stroke and acute kidney injury.Results: We found no statistically significant difference in mortality between patients treated with BEV vs. SEV during index procedure, at 30 days and at 1 year. BEVs showed a statistically significant higher risk of annulus rupture (2.5%) in comparison with SEV (0%) (OR 5.81 [95% CI, 3.78–8.92], p < .001). New generation BEVs were also associated with significantly less paravalvular leak when compared to new generation SEVs (OR 0.08 [95% CI, 0.02–0.35], p = .001).Conclusions: This meta‐analysis of observational studies of TAVI for bicuspid valves, showed no difference in short‐ and mid‐term TAVI mortality with BEVs and SEVs. BEVs presented a higher risk of annular rupture in comparison with SEV.
- 8 February 2021
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 98 (5) , E746-E757
Balloon versus self‐expandable transcatheter aortic valve implantation for bicuspid aortic valve stenosis: A meta‐analysis of observational studies
Background: There is a rising trend for transcatheter aortic valve implantation (TAVI) in bicuspid aortic stenosis patients. Data on the use of self‐expandable (SEV) vs. balloon‐expandable (BEV) valves in these patients are scarce. Therefore, we systematically compared clinical outcomes in bicuspid aortic stenosis patients treated with SEV and BEV.Methods: Data were extracted from PubMed/MEDLINE, EMBASE, CENTRAL/CCTR, ClinicalTrials.gov, SciELO, LILACS, Google Scholar and reference lists of relevant articles. Eight studies published from 2013 to 2020 including a total of 1,080 patients (BEV: n = 620; SEV: n = 460) were selected. Primary endpoints were procedural, 30‐day and 1‐year mortality. Secondary endpoints were new pacemaker implantation, annular rupture, coronary obstruction, moderate‐to‐severe paravalvular leak, need of second valve, stroke and acute kidney injury.Results: We found no statistically significant difference in mortality between patients treated with BEV vs. SEV during index procedure, at 30 days and at 1 year. BEVs showed a statistically significant higher risk of annulus rupture (2.5%) in comparison with SEV (0%) (OR 5.81 [95% CI, 3.78–8.92], p < .001). New generation BEVs were also associated with significantly less paravalvular leak when compared to new generation SEVs (OR 0.08 [95% CI, 0.02–0.35], p = .001).Conclusions: This meta‐analysis of observational studies of TAVI for bicuspid valves, showed no difference in short‐ and mid‐term TAVI mortality with BEVs and SEVs. BEVs presented a higher risk of annular rupture in comparison with SEV.
- Open Access
- 27 June 2020
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (29) , 2731-2742
Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves
Due to bioprosthetic valve degeneration, aortic valve-in-valve (ViV) procedures are increasingly performed. There are no data on long-term outcomes after aortic ViV. Our aim was to perform a large-scale assessment of long-term survival and reintervention after aortic ViV. A total of 1006 aortic ViV procedures performed more than 5 years ago [mean age 77.7 ± 9.7 years; 58.8% male; median STS-PROM score 7.3% (4.2–12.0)] were included in the analysis. Patients were treated with Medtronic self-expandable valves (CoreValve/Evolut, Medtronic Inc., Minneapolis, MN, USA) (n = 523, 52.0%), Edwards balloon-expandable valves (EBEV, SAPIEN/SAPIEN XT/SAPIEN 3, Edwards Lifesciences, Irvine, CA, USA) (n = 435, 43.2%), and other devices (n = 48, 4.8%). Survival was lower at 8 years in patients with small-failed bioprostheses [internal diameter (ID) ≤ 20 mm] compared with those with large-failed bioprostheses (ID > 20 mm) (33.2% vs. 40.5%, P = 0.01). Independent correlates for mortality included smaller-failed bioprosthetic valves [hazard ratio (HR) 1.07 (95% confidence interval (CI) 1.02–1.13)], age [HR 1.21 (95% CI 1.01–1.45)], and non-transfemoral access [HR 1.43 (95% CI 1.11–1.84)]. There were 40 reinterventions after ViV. Independent correlates for all-cause reintervention included pre-existing severe prosthesis–patient mismatch [subhazard ratio (SHR) 4.34 (95% CI 1.31–14.39)], device malposition [SHR 3.75 (95% CI 1.36–10.35)], EBEV [SHR 3.34 (95% CI 1.26–8.85)], and age [SHR 0.59 (95% CI 0.44–0.78)]. The size of the original failed valve may influence long-term mortality, and the type of the transcatheter valve may influence the need for reintervention after aortic ViV.
- 27 June 2020
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (29) , 2731-2742
Open AccessLong-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves
Due to bioprosthetic valve degeneration, aortic valve-in-valve (ViV) procedures are increasingly performed. There are no data on long-term outcomes after aortic ViV. Our aim was to perform a large-scale assessment of long-term survival and reintervention after aortic ViV. A total of 1006 aortic ViV procedures performed more than 5 years ago [mean age 77.7 ± 9.7 years; 58.8% male; median STS-PROM score 7.3% (4.2–12.0)] were included in the analysis. Patients were treated with Medtronic self-expandable valves (CoreValve/Evolut, Medtronic Inc., Minneapolis, MN, USA) (n = 523, 52.0%), Edwards balloon-expandable valves (EBEV, SAPIEN/SAPIEN XT/SAPIEN 3, Edwards Lifesciences, Irvine, CA, USA) (n = 435, 43.2%), and other devices (n = 48, 4.8%). Survival was lower at 8 years in patients with small-failed bioprostheses [internal diameter (ID) ≤ 20 mm] compared with those with large-failed bioprostheses (ID > 20 mm) (33.2% vs. 40.5%, P = 0.01). Independent correlates for mortality included smaller-failed bioprosthetic valves [hazard ratio (HR) 1.07 (95% confidence interval (CI) 1.02–1.13)], age [HR 1.21 (95% CI 1.01–1.45)], and non-transfemoral access [HR 1.43 (95% CI 1.11–1.84)]. There were 40 reinterventions after ViV. Independent correlates for all-cause reintervention included pre-existing severe prosthesis–patient mismatch [subhazard ratio (SHR) 4.34 (95% CI 1.31–14.39)], device malposition [SHR 3.75 (95% CI 1.36–10.35)], EBEV [SHR 3.34 (95% CI 1.26–8.85)], and age [SHR 0.59 (95% CI 0.44–0.78)]. The size of the original failed valve may influence long-term mortality, and the type of the transcatheter valve may influence the need for reintervention after aortic ViV.
- 5 August 2018
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 92 (6) , 1163-1170
Mortality prediction after transcatheter treatment of failed bioprosthetic aortic valves utilizing various international scoring systems: Insights from the Valve‐in‐Valve International Data (VIVID)
Background: Transcatheter Aortic Valve Implantation (TAVI) is commonly used to deploy new bioprosthetic valves inside degenerated surgically implanted aortic valves in high risk patients. The three scoring systems used to assess risk of postprocedural mortality are: Logistic EuroSCORE (LES), EuroSCORE II (ES II), and Society of Thoracic Surgeons (STS).Objective: The purpose of this study is to analyze the accuracy of LES, ES II, and STS in estimating all‐cause mortality after transcatheter aortic valve‐in‐valve (ViV) implantations, which was not assessed before.Methods: Using the Valve‐in‐Valve International Data (VIVID) registry, a total of 1,550 patients from 110 centers were included. The study compared the observed 30‐day overall mortality vs. the respective predicted mortalities calculated by risk scores. The accuracy of prediction models was assessed based on calibration and discrimination.Results: Observed mortality at 30 days was 5.3%, while average expected mortalities by LES, ES II and STS were 29.49 (± 17.2), 14.59 (± 8.6), and 9.61 (± 8.51), respectively. All three risk scores overestimated 30‐day mortality with ratios of 0.176 (95% CI 0.138–0.214), 0.342 (95% CI 0.264–0.419), and 0.536 (95% CI 0.421–0.651), respectively. 30‐day mortality ROC curves demonstrated that ES II had the largest AUC at 0.722, followed by STS at 0.704, and LES at 0.698.Conclusions: All three scores overestimated mortality at 30 days with ES II showing the highest predictability compared to LES and STS; and therefore, should be recommended for ViV procedures. There is a need for a dedicated scoring system for patients undergoing ViV interventions.
- 5 August 2018
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 92 (6) , 1163-1170
Mortality prediction after transcatheter treatment of failed bioprosthetic aortic valves utilizing various international scoring systems: Insights from the Valve‐in‐Valve International Data (VIVID)
Background: Transcatheter Aortic Valve Implantation (TAVI) is commonly used to deploy new bioprosthetic valves inside degenerated surgically implanted aortic valves in high risk patients. The three scoring systems used to assess risk of postprocedural mortality are: Logistic EuroSCORE (LES), EuroSCORE II (ES II), and Society of Thoracic Surgeons (STS).Objective: The purpose of this study is to analyze the accuracy of LES, ES II, and STS in estimating all‐cause mortality after transcatheter aortic valve‐in‐valve (ViV) implantations, which was not assessed before.Methods: Using the Valve‐in‐Valve International Data (VIVID) registry, a total of 1,550 patients from 110 centers were included. The study compared the observed 30‐day overall mortality vs. the respective predicted mortalities calculated by risk scores. The accuracy of prediction models was assessed based on calibration and discrimination.Results: Observed mortality at 30 days was 5.3%, while average expected mortalities by LES, ES II and STS were 29.49 (± 17.2), 14.59 (± 8.6), and 9.61 (± 8.51), respectively. All three risk scores overestimated 30‐day mortality with ratios of 0.176 (95% CI 0.138–0.214), 0.342 (95% CI 0.264–0.419), and 0.536 (95% CI 0.421–0.651), respectively. 30‐day mortality ROC curves demonstrated that ES II had the largest AUC at 0.722, followed by STS at 0.704, and LES at 0.698.Conclusions: All three scores overestimated mortality at 30 days with ES II showing the highest predictability compared to LES and STS; and therefore, should be recommended for ViV procedures. There is a need for a dedicated scoring system for patients undergoing ViV interventions.
- 1 October 2015
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 11 (6) , 682-689
New Braile Inovare transcatheter aortic prosthesis: clinical results and follow-up
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 October 2015
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 11 (6) , 682-689
New Braile Inovare transcatheter aortic prosthesis: clinical results and follow-up
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)